1226 results about "Cardiac arrhythmia" patented technology

Devices, systems and methods are disclosed for the ablation of tissue and treatment of cardiac arrhythmia. An ablation system includes an ablation catheter that has an array of ablation elements and a location element, an esophageal probe also including a location element, and an interface unit that provides energy to the ablation catheter. The distance between the location elements, determined by calculating means of the system, can be used by the system to set or modify one or more system parameters.

Apparatus is provided including an implantable sensor, adapted to sense an electrical parameter of a heart of a subject, and a first control unit, adapted to apply pulses to the heart responsively to the sensed parameter, the pulses selected from the list consisting of: pacing pulses and anti-arrhythmic energy. The apparatus further includes an electrode device, adapted to be coupled to a site of the subject selected from the list consisting of: a vagus nerve of the subject, an epicardial fat pad of the subject, a pulmonary vein of the subject, a carotid artery of the subject, a carotid sinus of the subject, a coronary sinus of the subject, a vena cava vein of the subject, a right ventricle of the subject, and a jugular vein of the subject; and a second control unit, adapted to drive the electrode device to apply to the site a current that increases parasympathetic tone of the subject and affects a heart rate of the subject. The first and second control units are not under common control. At least one of the control units is adapted to coordinate an aspect of its operation with an aspect of operation of the other control unit. Other embodiments are also described.

A catheter assembly and method for treatment of cardiac arrhythmia, for example, atrial fibrillation, by electrically isolating a vessel, such as a pulmonary vein, from a chamber, such as the left atrium. The catheter assembly includes a catheter body and at least one electrode. The catheter body includes a proximal portion, an intermediate portion and a distal portion. The intermediate portion extends from the proximal portion and defines a longitudinal axis. The distal portion extends from the intermediate portion and forms a substantially closed loop transverse to the longitudinal axis. The at least one electrode is disposed along the loop. With this configuration, the loop is axially directed into contact with the chamber wall about the vessel ostium. Upon energization, the electrode ablates a continuous lesion pattern about the vessel ostium, thereby electrically isolating the vessel from the chamber.

Novel devices and methods that affect the neurologic and biological electrical conduction systems for the treatment various neurological and physiological disorders. Localized mechanical forces imparted by the inventive devices and methods modify or alter the mechanoelectric and or electrochemical properties of the affected tissues and biologic systems. Combinations of various technologies can be incorporated into the devices and methodologies for specific treatments. The devices and methods can be used to treat a number of neurologic and physiologic disorders such as Parkinson's, epilepsy, atrial fibrillation, cardiac arrhythmia, obesity, and others.

A cardiac monitor is provided that monitors the condition of the heart of a cardiac patient and generates signals indicating one of several conditions, such as supraventricular tachycardia, ventricular tachycardia and ventricular fibrillation. In order to generate these signals, the ECG from the patient is analyzed to determine a cardiac interval and heart rate, as well as a waveform factor and a waveform factor irregularity. The waveform factor is derived from the average of the ECG amplitudes during a cardiac interval and the peak value of the ECG during the same interval. Preferably, a running average is calculated over several intervals. This waveform factor is then used to detect shockable ventricular arrhythmia. The waveform factor irregularity is indicative of the variability of the waveform factor and is used to differentiate between ventricular tachycardia and ventricular defibrillation.

An apparatus and method for controlling the orientation, geometry, shape or length of an inserted catheter is provided to optimize it's position during procedures for treating cardiac arrhythmia by ablation based on functions derived from one or more parameters including the temporal relationship between intracardiac signals, patient anatomy, cardiac tissue electrical properties, imaging data, and other criteria that may include previously stored data collected from one or more patients who have had successful therapy delivered.

The present invention relates to comprehensive systems, devices and methods for delivering energy to tissue for a wide variety of applications, including medical procedures (e.g., tissue ablation, resection, cautery, vascular thrombosis, treatment of cardiac arrhythmias and dysrhythmias, electrosurgery, tissue harvest, etc.). In certain embodiments, systems, devices, and methods are provided for treating a tissue region (e.g., a tumor) through application of energy.

A non-invasive bodily-attached ambulatory medical monitoring and treatment device with pacing is provided. The noninvasive ambulatory pacing device includes a battery, at least one therapy electrode coupled to the battery, a memory storing information indicative of a patient's cardiac activity, and at least one processor coupled to the memory and the at least one therapy electrode. The at least one processor is configured to identify a cardiac arrhythmia within the information and execute at least one pacing routine to treat the identified cardiac arrhythmia.

In an embodiment, the invention includes an implantable medical device with a pulse generator and a chemical sensor in communication with the pulse generator, the chemical sensor configured to detect an ion concentration in a bodily fluid. In an embodiment, the invention includes a method for providing cardiac arrhythmia therapy to a patient including sensing a physiological concentration of an analyte, communicating data regarding the physiological concentration of the analyte to an implanted pulse generator, and delivering therapy to the patient based in part on the physiological concentration of the ion. In an embodiment, the invention includes a method for monitoring diuretic therapy. In an embodiment, the invention includes a method for controlling delivery of an active agent into a human body. Other aspects and embodiments are provided herein.

A method is provided for ablation in treatment of heart arrhythmias such as atrial fibrillation that includes positioning a catheter apparatus with multiple electrodes within a cardiac chamber, visualizing the catheter apparatus with an interventional system, navigating the catheter apparatus within the cardiac chamber, and delivering energy to selected electrodes of the catheter apparatus from an external source to ablate heart tissue at select locations. Preferably, the external source is an external patch placed on the patient for the delivery of radio-frequency energy. The electrodes of the catheter apparatus are connected to the patch through a patient interface unit where the interface unit selects the electrodes to which radio-frequency energy is to be delivered. In another aspect of the invention, a system for ablation of heart arrhythmias is provided that has a catheter apparatus with multiple electrodes, an interventional system for visualizing the catheter apparatus within a cardiac chamber, and an external source for delivering energy to selected electrodes of the catheter apparatus within the cardiac chamber to ablate heart tissue. Preferably, the system further includes a digital imaging system for obtaining cardiac image data, an image generation system for generating a 3D model of the cardiac chamber from the cardiac image data, and a workstation for registering the 3D model with the interventional system and for visualizing the catheter apparatus over this registered 3D model upon the interventional system.

Devices and methods for single therapy pulse (STP) therapy for tachyarrythmia are disclosed. The STP therapy can be delivered from a far-field position to allow a “global” capture approach to pacing. Due to the global capture in STP, a series of pulses, which is indicative of conventional anti-tachycardia pacing (ATP) delivered by transvenous systems, becomes unnecessary. One to four pulses at most are needed for STP, and after delivery of the one to four pulses, therapy delivery can be interrupted to determine whether the previously delivered therapy has been successful.

Devices and methods provide for ablation of cardiac tissue for treating cardiac arrhythmias such as atrial fibrillation. Although the devices and methods are often be used to ablate epicardial tissue in the vicinity of at least one pulmonary vein, various embodiments may be used to ablate other cardiac tissues in other locations on a heart. Devices generally include at least one tissue contacting member for contacting epicardial tissue and securing the ablation device to the epicardial tissue, and at least one ablation member for ablating the tissue. Various embodiments include features, such as suction apertures, which enable the device to attach to the epicardial surface with sufficient strength to allow the tissue to be stabilized via the device. For example, some embodiments may be used to stabilize a beating heart to enable a beating heart ablation procedure. Many of the devices may be introduced into a patient via minimally invasive introducer devices and the like. Although devices and methods of the invention may be used to ablate epicardial tissue to treat atrial fibrillation, they may also be used in veterinary or research contexts, to treat various heart conditions other than atrial fibrillation and/or to ablate cardiac tissue other than the epicardium.

An implantable devices for the effective elimination of an arrhythmogenic site from the myocardium is presented. By inserting small biocompatible conductors and/or insulators into the heart tissue at the arrhythmogenic site, it is possible to effectively eliminate a portion of the tissue from the electric field and current paths within the heart. The device would act as an alternative to the standard techniques for the removal of tissue from the effective contribution to the hearts electrical action which require the destruction of tissue via energy transfer (RF, microwave, cryogenic, etc.). This device is a significant improvement in the state of the art in that it does not require tissue necrosis.In one preferred embodiment the device is a non conductive helix that is permanently implanted into the heart wall around the arrhythmogenic site. In variations on the embodiment, the structure is wholly or partially conductive, the structure is used as an implantable substrate for anti arrhythmic, inflammatory, or angiogenic pharmacological agents, and the structure is deliverable by a catheter with a disengaging stylet. In other preferred embodiments that may incorporate the same variations, the device is a straight or curved stake, or a group of such stakes that are inserted simultaneously.

A method and apparatus for adjusting a sensing parameter in a medical device that includes a sensing electrode sensing cardiac signals, a processor to determine an adjusting characteristic associated with the cardiac signals sensed over a predetermined sensing window, and a control unit to update the sensing parameter in response to the determined adjusting characteristic.

A method of controlling a remote navigation system that orients the distal end of a medical device in response to user inputs, includes interrupting the operation of the remote navigation system when the user inputs would navigate the medical device to a location where the impedance exceeds a predetermined value. A method of controlling ablation of cardiac tissue to block an errant signal causing an arrhythmia includes ablating tissue until there is a predetermined reduction in the amplitude of the errant signal or a predetermined reduction in local impedance. Controls remote navigation systems can implement these methods.

A heart monitor for use as a non-invasive screening tool for identifying potential atrial fibrillation in patients comprises a sensor for producing an output waveform of the patient's actual sinus rhythm, a processing unit arranged to store the normalised waveform of an ideal sinus rhythm and to compare the actual and ideal sinus rhythm waveforms and to produce an output dependant on the difference on a display. The value of the output is indicative of whether the patient is atrial fibrillation or other cardiac arrhythmia.